Advertisement

World Journal of Surgery

, Volume 43, Issue 4, pp 1162–1172 | Cite as

Prognostic Factors of Pathological N1 Non-small Cell Lung Cancer After Curative Resection Without Adjuvant Chemotherapy

  • Youngkyu MoonEmail author
  • Sook Whan Sung
  • Jae Kil Park
  • Kyo Young Lee
  • Seha Ahn
Original Scientific Report

Abstract

Background

The aim of this study was to evaluate the outcomes of patients with pathological N1 non-small cell lung cancer who did not receive adjuvant chemotherapy. We attempted to identify those patients for whom adjuvant chemotherapy would be indispensable.

Methods

Among 132 patients who were diagnosed with pathological N1 lung cancer at a single institution from January 2010 to December 2016 were 32 patients who did not receive adjuvant treatment after curative surgical resection. The surgical and oncological outcomes of these patients were analyzed. Candidate factors for predicting recurrence were analyzed to identify patients at high risk of recurrence.

Results

The median follow-up time for all 32 patients was 1044 days. The 5-year recurrence-free survival (RFS) and disease-specific survival rates of the patients without adjuvant therapy were 50.3% and 77.6%, respectively. By multivariate analysis, tumors with a lepidic growth pattern [hazard ratio (HR) 0.119, p = 0.024] and extralobar lymph node metastasis (HR 6.848, p = 0.015) were significant factors predicting recurrence. The difference between the 5-year RFS rates of patients with tumors with or without a lepidic growth pattern was statistically significant (63.5% vs 40.0%, respectively; p = 0.050). The 5-year RFS rates of patients with intralobar lymph node metastasis versus those with extralobar lymph node metastasis were 63.3% and 18.8%, respectively (p = 0.002).

Conclusions

Patients with tumors without a lepidic growth pattern or with extralobar lymph node metastasis who do not receive adjuvant chemotherapy have a high recurrence rate after surgery. Therefore, these patients should be encouraged to undergo adjuvant chemotherapy if their overall condition is not a contraindication for chemotherapy.

Notes

Compliance with ethical standards

Conflicts of interest

The authors have no conflicts of interest to declare.

References

  1. 1.
    Yang L, Wang S, Zhou Y et al (2017) Evaluation of the 7(th) and 8(th) editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort. Oncotarget 8:66784–66795PubMedPubMedCentralGoogle Scholar
  2. 2.
    Douillard JY, Tribodet H, Aubert D et al (2010) Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol 5:220–228CrossRefPubMedGoogle Scholar
  3. 3.
    Berry MF, Coleman BK, Curtis LH et al (2015) Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients. Ann Surg Oncol 22:642–648CrossRefPubMedGoogle Scholar
  4. 4.
    Isaka M, Kojima H, Takahashi S et al (2018) Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: implications for adjuvant therapy. Lung Cancer 115:28–33CrossRefPubMedGoogle Scholar
  5. 5.
    Park BJ, Cho JH, Lee JH et al (2018) Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: the effect of postoperative adjuvant chemotherapy. Lung Cancer 117:7–13CrossRefPubMedGoogle Scholar
  6. 6.
    Hattori A, Matsunaga T, Takamochi K et al (2017) Importance of ground glass opacity component in clinical stage IA radiologic invasive lung cancer. Ann Thorac Surg 104:313–320CrossRefPubMedGoogle Scholar
  7. 7.
    Moon Y, Sung SW, Lee KY et al (2016) The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma. World J Surg Oncol 14:37CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Eguchi T, Kadota K, Park BJ et al (2014) The new IASLC–ATS–ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg 26:210–222CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Maeshima AM, Tsuta K, Asamura H et al (2012) Prognostic implication of metastasis limited to segmental (level 13) and/or subsegmental (level 14) lymph nodes in patients with surgically resected nonsmall cell lung carcinoma and pathologic N1 lymph node status. Cancer 118:4512–4518CrossRefPubMedGoogle Scholar
  10. 10.
    Asamura H, Chansky K, Crowley J et al (2015) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol 10:1675–1684CrossRefPubMedGoogle Scholar
  11. 11.
    Haney JC, Hanna JM, Berry MF et al (2014) Differential prognostic significance of extralobar and intralobar nodal metastases in patients with surgically resected stage II non-small cell lung cancer. J Thorac Cardiovasc Surg 147:1164–1168CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Douillard JY, Rosell R, De Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719–727CrossRefPubMedGoogle Scholar
  13. 13.
    Salazar MC, Rosen JE, Wang Z et al (2017) Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol 3:610–619CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lu P, Sun Y, Sun Y et al (2014) The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma. Lung Cancer 85:53–58CrossRefPubMedGoogle Scholar
  15. 15.
    Moon Y, Kim KS, Lee KY et al (2016) Clinicopathologic factors associated with occult lymph node metastasis in patients with clinically diagnosed N0 lung adenocarcinoma. Ann Thorac Surg 101:1928–1935CrossRefPubMedGoogle Scholar
  16. 16.
    Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243–1260CrossRefPubMedGoogle Scholar
  17. 17.
    Rusch VW, Asamura H, Watanabe H et al (2009) The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4:568–577CrossRefPubMedGoogle Scholar
  18. 18.
    Jonnalagadda S, Smith C, Mhango G et al (2011) The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer. Chest 140:433–440CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Jonnalagadda S, Arcinega J, Smith C et al (2011) Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer. Cancer 117:4724–4731CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Moon Y, Kim KS, Sung SW et al (2014) Correlation of histological components with tumor invasion in pulmonary adenocarcinoma. World J Surg Oncol 12:388CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Moon Y, Lee KY, Sung SW et al (2016) Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations. J Thorac Dis 8:169–177PubMedPubMedCentralGoogle Scholar
  22. 22.
    Kadota K, Villena-Vargas J, Yoshizawa A et al (2014) Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol 38:448–460CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tremblay L, Deslauriers J (2013) What is the most practical, optimal, and cost effective method for performing follow-up after lung cancer surgery, and by whom should it be done? Thorac Surg Clin 23:429–436CrossRefPubMedGoogle Scholar
  24. 24.
    Kiankhooy A, Taylor MD, LaPar DJ et al (2014) Predictors of early recurrence for node-negative t1 to t2b non-small cell lung cancer. Ann Thorac Surg 98:1175–1183CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2018

Authors and Affiliations

  • Youngkyu Moon
    • 1
    Email author
  • Sook Whan Sung
    • 1
  • Jae Kil Park
    • 1
  • Kyo Young Lee
    • 2
  • Seha Ahn
    • 1
  1. 1.Department of Thoracic and Cardiovascular SurgerySeoul St. Mary’s Hospital, College of Medicine, The Catholic University of KoreaSeoulRepublic of Korea
  2. 2.Department of Hospital PathologySeoul St. Mary’s Hospital, College of Medicine, The Catholic University of KoreaSeoulRepublic of Korea

Personalised recommendations